Vanderbilt University Medical Center
Vanderbilt University Medical Center
Nashville, Tennessee, United States7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258) | Acute Decompensated Heart Failure | Recruiting | Phase 3 | 2026-10-08 | NCT06898515 | |
| American Lung Association (ALA) Lung Health Cohort | lung disorder, respiratory system disorder | Recruiting | Not stated | 2026-09-23 | NCT04543461 | |
| The HOPE Biobank Resource (BMT CTN 2402 HOPE) | Bone Marrow Failure, Bone Marrow Failure Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder, hereditary disease, inherited hemoglobinopathy | Recruiting | Not stated | 2026-08-27 | NCT07227155 | |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-18 | NCT06412666 | |
| Subcortical Arousal in Perceptual Awareness | brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Not applicable | 2026-08-10 | NCT06934356 | |
| Tumor-induced Osteomalacia Disease Monitoring Program | Oncogenic osteomalacia | Active, not recruiting | Not stated | 2026-06-03 | NCT04783428 | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, hematologic disorder, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm, superficial spreading melanoma, type III hypersensitivity disease | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05186753 |